Key result
Genetic deficiency in tissue kallikrein (KLK1) in mouse and human models demonstrates its critical role in arterial function, renal ionic transport, and cardio- and nephro-protection.
Genetic models of tissue kallikrein deficiency highlight its critical protective roles in arterial function, cardiac ischemia, and heart failure.
Answers are grounded in this paper and cite their sources.
KLK1 deficiency models support protective cardio-renal roles; hypothesis-generating for therapeutic targeting pending clinical studies.
Tissue kallikrein (KLK1) is a kinin-forming serine protease synthesized in many organs including arteries and kidney. Study of the physiological role of KLK1 has benefited from the availability of mouse and human genetic models of KLK1 deficiency, through engineering of KLK1 mouse mutants and discovery of a major polymorphism in the human KLK1 gene that induces a loss of enzyme activity. Studies in KLK1-deficient mice and human subjects partially deficient in KLK1 have documented its critical role in arterial function in both species. KLK1 is also involved in the control of ionic transport in the renal tubule, an action that may not be kinin-mediated. Studies of experimental diseases in KLK1-deficient mice have revealed cardio- and nephro-protective effects of KLK1 and kinins in acute cardiac ischemia, post-ischemic heart failure, and diabetes. Potential clinical and therapeutic developments are discussed.
No takes yet. Share an insight, caveat, or question.
Pizard et al. (2008) conducted a review in Tissue kallikrein (KLK1) deficiency. Genetic deficiency in tissue kallikrein (KLK1) was evaluated. Genetic deficiency in tissue kallikrein (KLK1) in mouse and human models demonstrates its critical role in arterial function, renal ionic transport, and cardio- and nephro-protection.
Synapse has enriched 10 related papers. Consider them for comparative context: